Retinopathy of Prematurity-Induced Blindness: Birth Weight-Specific Survival and the New Epidemic

PEDIATRICS ◽  
1990 ◽  
Vol 86 (3) ◽  
pp. 405-412
Author(s):  
Donna L. Gibson ◽  
Samuel B. Sheps ◽  
Soo Hong ◽  
Martin T. Schechter ◽  
Andrew Q. McCormick

A recent population-based study in the Canadian province of British Columbia showed that, since the mid-1960s, there has been a significant increase in the incidence of retinopathy of prematurity-induced blindness in infants weighing 750 to 999 g at birth. To determine the impact of changing birth weight-specific survival on this new epidemic, all infants born in the province in the period 1952 through 1986 and known to the British Columbia Health Surveillance Registry as having retinopathy of prematurity-induced blindness were identified. In addition, the birth registration records for the 1 299 740 infants born in British Columbia in the same period and the death records of the 22 940 British Columbia-born infants who died in the province before the end of their first year of life were linked using a combination of probabilistic and manual record linkage techniques. These linked records and the records from the Health Surveillance Registry were used to calculate birth weight-specific incidence rates of retinopathy of prematurity-induced blindness in liveborn infants and first-year-of-life survivors. The rates, in 5-year intervals, showed that, in both liveborn infants and first-year survivors, the highest birth weight-specific rates occurred during the first epidemic of retinopathy of prematurity, which ended in British Columbia in 1954. Since the mid- to late-1960s, the incidence of retinopathy of prematurity-induced blindness in liveborn infants weighing less than 1000 g increased steadily whereas in infants weighing 1000 to 1499 g, incidence decreased slightly since the original epidemic ended. However, the experience of first-year-of-life survivors is substantially different. In survivors weighing 500 to 749 g at birth, incidence has decreased since the mid-1970s, whereas in survivors weighing 750 to 999 g, incidence has been stable since 1965. In infants weighing 1000 to 1499 g, the slight trend toward decreasing rates observed in livebirths since the end of the original epidemic is more pronounced. Thus, these results substantiate the idea that the new epidemic of retinopathy of prematurity-induced blindness in infants weighing less than 1000 g is a function of increasing birth weight-specific survival.

BMJ Open ◽  
2021 ◽  
Vol 11 (5) ◽  
pp. e048744
Author(s):  
Andreea Bratu ◽  
Taylor McLinden ◽  
Katherine Kooij ◽  
Monica Ye ◽  
Jenny Li ◽  
...  

IntroductionPeople living with HIV (PLHIV) are increasingly at risk of age-related comorbidities such as diabetes mellitus (DM). While DM is associated with elevated mortality and morbidity, understanding of DM among PLHIV is limited. We assessed the incidence of DM among people living with and without HIV in British Columbia (BC), Canada, during 2001–2013.MethodsWe used longitudinal data from a population-based cohort study linking clinical data and administrative health data. We included PLHIV who were antiretroviral therapy (ART) naïve at baseline, and 1:5 age-sex-matched persons without HIV. All participants had ≥5 years of historic data pre-baseline and ≥1 year(s) of follow-up. DM was identified using the BC Ministry of Health’s definitions applied to hospitalisation, physician billing and drug dispensation datasets. Incident DM was identified using a 5-year run-in period. In addition to unadjusted incidence rates (IRs), we estimated adjusted incidence rate ratios (IRR) using Poisson regression and assessed annual trends in DM IRs per 1000 person years (PYs) between 2001 and 2013.ResultsA total of 129 PLHIV and 636 individuals without HIV developed DM over 17 529 PYs and 88,672 PYs, respectively. The unadjusted IRs of DM per 1000 PYs were 7.4 (95% CI 6.2 to 8.8) among PLHIV and 7.2 (95% CI 6.6 to 7.8) for individuals without HIV. After adjustment for confounding, HIV serostatus was not associated with DM incidence (adjusted IRR: 1.03, 95% CI 0.83 to 1.27). DM incidence did not increase over time among PLHIV (Kendall trend test: p=0.9369), but it increased among persons without HIV between 2001 and 2013 (p=0.0136).ConclusionsAfter adjustment, HIV serostatus was not associated with incidence of DM, between 2001 and 2013. Future studies should investigate the impact of ART on mitigating the potential risk of DM among PLHIV.


Epilepsia ◽  
2016 ◽  
Vol 57 (10) ◽  
pp. 1594-1601 ◽  
Author(s):  
Eija Gaily ◽  
Markus Lommi ◽  
Risto Lapatto ◽  
Anna-Elina Lehesjoki

PEDIATRICS ◽  
1989 ◽  
Vol 83 (4) ◽  
pp. 486-492
Author(s):  
Donna L. Gibson ◽  
Samuel B. Sheps ◽  
Martin T. Schechter ◽  
Sandra Wiggins ◽  
Andrew Q. McCormick

This study provides the first empiric evidence for the existence of a new epidemic of retinopathy of prematurity-induced blindness. Data from a population-based register of handicapping conditions in the Canadian province of British Columbia, and a birth weight-specific census of live-born infants in British Columbia, were used to determine annual, population-level incidences of retinopathy of prematurity-induced blindness during 1952 to 1983. Changes in incidence since the end of the original epidemic (1954) were determined by subdividing the 29-year period (1955 to 1983) into two intervals (1955 to 1964 and 1965 to 1983). Standardized incidence ratio analyses revealed a marginally significant increase in the overall incidence of retinopathy of prematurity-induced blindness in the later as compared with the earlier period. Infants weighing 750 to 999 g at birth had a significantly increased standardized incidence ratio of 3.07 (95% confidence interval 1.26, 11.06). No increases in risk were observed in heavier or lighter weight infants. Because ascertainment and diagnostic changes do not explain the weight-specific increases in incidence, these results provide the first population-level evidence for a new epidemic.


Epilepsia ◽  
2007 ◽  
Vol 48 (9) ◽  
pp. 1724-1730 ◽  
Author(s):  
Evald Saemundsen ◽  
Petur Ludvigsson ◽  
Ingibjorg Hilmarsdottir ◽  
Vilhjalmur Rafnsson

The Prostate ◽  
2007 ◽  
Vol 67 (11) ◽  
pp. 1247-1254 ◽  
Author(s):  
Margaretha Eriksson ◽  
Hans Wedel ◽  
Mari-Ann Wallander ◽  
Ingvar Krakau ◽  
Jonas Hugosson ◽  
...  

2012 ◽  
Vol 30 (4_suppl) ◽  
pp. 184-184 ◽  
Author(s):  
Moises Cukier ◽  
Calvin Law ◽  
Ning Liu ◽  
Refik Saskin ◽  
Simron Singh

184 Background: A recent study of the SEER database in the United States showed a 5-fold increase in neuroendocrine tumours (NETs) over the last 30 years. An increasing incidence has also been reported in Norway, Sweden, England, Holland, Italy and Japan, but interestingly not in Denmark and Switzerland. The objective of our study is to describe the incidence, anatomical distribution and survival of NETs in Ontario. Methods: A population based study was initiated using the Ontario Cancer Registry, cross-linked with the Registered Persons Database and the Canadian Institute of Health Information Discharge Abstract Database. All cases of NETs were identified in Ontario (> 13 million persons) from 1994 to 2009. Baseline demographic, clinical and outcomes data were abstracted to allow for an analysis of annual incidence rates, and overall survival. Results: A total of N = 5619 cases were identified. The incidence rate increased from 2.46/ 100,000 (95% CI, 2.13-2.83) in 1994 to 5.86/ 100,000 (95% CI, 5.40 – 6.35) in 2009. The median age was 62 with 50.5% female cases. When divided by site, bronchopulmonary NETs where the most common (22%), then jejunum/ileum (17%) and rectal (16%) NETs, while pancreatic NETs (pNETs) and gastric NETs were 10% and 5% respectively. The absolute increase in the study period was most pronounced for pNETs (6-fold), rectal (5-fold) and gastric (5-fold) NETs. Metastatic disease was documented in 45% of the cases; 20% at diagnosis and 25% during follow-up. The 5-and 10-year overall survival (OS) was 61% and 46% respectively, for the entire population. Site specific 5-year OS were: rectal (87.0%), small bowel (73.4%), gastric (67.4%), colon (64.3%) and pancreas (48.8%). 5-year OS was compared for patients with and without metastatic disease after diagnosis (69.0% vs 40.1%, p<0.0001). Conclusions: There appears to be a significant increase of reported cases of NETs in Ontario, Canada, particularly pNETs, rectum NETs and gastric NETs. This supports much of the population-based reports worldwide. Survival appears to vary significantly according to anatomical site and extent of disease. Further research is required to understand the impact of this cancer previously perceived to be rare but clearly increasing.


2013 ◽  
Vol 163 (4) ◽  
pp. 1014-1019 ◽  
Author(s):  
Samantha J. Lain ◽  
Natasha Nassar ◽  
Jennifer R. Bowen ◽  
Christine L. Roberts

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 8049-8049 ◽  
Author(s):  
Abdulwahab J. Al-Tourah ◽  
Laurie Helen Sehn ◽  
Alden A Moccia ◽  
Randy D. Gascoyne ◽  
Joseph M. Connors

8049 Background: Several published series have established that the risk of transformation of follicular lymphoma (FL) to aggressive lymphoma is approximately 3% /year (15%-20% at 5 years). The addition of rituximab (R) to chemotherapy (immuno-chemotherapy) has significantly improved the outcome of patients with FL. The impact of immuno-chemotherapy on the risk of transformation remains unknown. We assessed whether the introduction of immuno-chemotherapy has altered this risk. Methods: We examined the Lymphoid Cancer Database of the British Columbia Cancer Agency for FL patients treated with immuno-chemotherapy. Inclusion criteria: FL grades 1-3A by WHO criteria; only patients requiring treatment at diagnosis were included. Exclusion criteria: FL grade 3B or composite histology (FL and DLBCL) at diagnosis; pts who received anthracycline-based chemotherapy; and HIV positivity. The diagnosis of transformation was confirmed by biopsy when possible (n=19; 79%) but patients who were considered to have transformed based on pre-defined clinical assessment (n=5; 21%) were also included in the analysis. Results: We identified 261 pts with FL grade 1-3A requiring treatment at diagnosis, who received immuno-chemotherapy; median f/u 47 months (0.2-116), median age, 61 y (34-86). Treatment: 243 (93%), R-CVP of which 145 (59%) also received maintenance R; 9 (4%), R-Fludarabine combination. 24 pts developed transformed aggressive lymphoma. The risk of transformation for the entire group was approximately 2% per year or 10% at 5 years. However, pts treated with maintenance R (n=151) had a lower risk of transformation compared to pts who only received R-chemo at induction (n= 110), 8% vs 20% at 5 years respectively, (P= 0.003). The post-transformation outcome remains poor with a median survival of 6 months. Conclusions: We and other groups have demonstrated that the risk of transformation from FL to aggressive lymphoma is approximately 15% to 20% by 5 years. Our study suggests that the introduction of immuno-chemotherapy has reduced this risk to less than 10%. This effect is particularly apparent when patients receive maintenance R. The outcome for patients who develop transformation remains poor.


Sign in / Sign up

Export Citation Format

Share Document